CVS Caremark to Cover Eli Lilly Weight Loss Drugs
CVS Caremark, a major pharmacy benefits manager, announced today that it will now cover Eli Lilly’s weight loss medications, including Zepbound and Mounjaro. This decision is expected to significantly impact Eli Lilly’s sales and accessibility of these treatments for CVS Caremark members.
The inclusion of Eli Lilly’s weight loss drugs in CVS Caremark’s formulary means that millions of individuals enrolled in plans managed by CVS Caremark may now have access to these medications, potentially at a reduced cost depending on their specific plan coverage. Previously, the high cost of these drugs has been a barrier for many patients seeking weight management solutions.
Eli Lilly has seen substantial demand for Zepbound and Mounjaro, which have garnered attention for their effectiveness in promoting weight loss and managing type 2 diabetes, respectively. Analysts predict that broader insurance coverage will further fuel this demand, leading to increased revenue for the pharmaceutical company. The company's stock has already shown positive reactions to the news.
While the specific details of coverage, including co-pays and prior authorization requirements, will vary depending on individual health plans, this move by CVS Caremark represents a major step towards making these weight loss medications more readily available to a wider population. Experts believe this is a positive development for both patients and Eli Lilly, although the long-term impact on healthcare costs remains to be seen. The news reinforces the view that Eli Lilly remains a strong investment option, even considering its current stock valuation.
